Preclinical approaches in vulvovaginal candidiasis treatment with mucoadhesive thermoresponsive systems containing propolis

• DOI: 10.1371/journal.pone.0243197
• Publication Date: 2020-12-11T18:28:39Z
• Authors: Amanda Pohlmann B...; Karina Mayumi Sakita; Daniella Renata F...; Glaucia Sayuri Arita; Franciele Abigail...; Isis Regina Greni...; Andressa Gimenes ...; Rafaela Said dos ...; Marcos Luciano Br...; Tania Cristina Al...; Admilton Gonçalve...; Érika Seki Kioshima; Patrícia de Souza...; Terezinha Inez Es...
• Keywords: Propolis; Nystatin; Vulvovaginal Candidiasis

Vulvovaginal candidiasis (VVC) is a common vaginitis that affects women, especially in childbearing age, caused by Candida albicans almost 80% of cases. Considering the limited drug arsenal available and increasing fungal resistance profile, search for new therapeutic sources with low toxicity easy administration should be supported. Propolis has been used as traditional medicine multiple diseases, considering its particular composition pharmaceutical properties permits wide applicability; it also emerged potential antifungal agent. Thus, this study performed an vitro vivo investigation into efficacy mucoadhesive thermoresponsive platform propolis delivery (MTS-PRPe) preclinical murine model VVC treatment C . The methodologies involved chemical analysis, assessment rheological formulations, evaluations, histological evaluations electron microscopy vaginal mucosa. results demonstrated activity extract MTS-PRP against standard strain fluconazole-resistant clinical isolate , both assays. These were similar even better, depending on concentration, when compared to nystatin. formulation containing exhibited good performance albican s vulvovaginal experimental model, representing promising opportunity infection.